Business
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
ZUG, Switzerland, February 27, 2026--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.1 Results will be presented at 2026 Winter Clinical Miami
About this update from Galderma Group Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/905ca7970f8a217bdf6fe3eca5286ff4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MuoOFBdvZwt6TR3sqb_Crg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/905ca7970f8a217bdf6fe3eca5286ff4","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LMzNmRCBn0SYWZKdcwWLLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/905ca7970f8a217bdf6fe3eca5286ff4","width":823,"height":209}}},{"type":"list","items":[{"val":[{"type":"text","content":"Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1","length":247,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported to date1","length":128,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Nemluvio is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis2-5","length":197,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the United States (U.S.) and European Union (EU)4,5","length":218,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":790,"olType":false},{"type":"text","content":"ZUG, Switzerland, February 27, 2026--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to...